• PURPOSE: This is a 2-part study of pembrolizumab (MK-3475) in pediatric participants who have either advanced melanoma or a programmed cell death ligand 1 (PD-L1)-positive advanced, relapsed or refractory solid tumor or lymphoma. (cincinnatichildrens.org)
  • This multicenter, open-label phase 2 study evaluated buparlisib (BKM120), a pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or refractory non-Hodgkin lymphoma. (haematologica.org)
  • Buparlisib showed activity in relapsed or refractory non-Hodgkin lymphoma, with disease stabilization and sustained tumor burden reduction in some patients, and acceptable toxicity. (haematologica.org)
  • The aim of the present study was to assess the effects of sprouty homolog 2 (SPRY2) gene regulation by miR-21 on the occurrence, development and tumor metastasis in multiple myeloma (MM). The miR‑21 expression lentiviral vector (LV)‑anti‑miR‑21 and a liposome transfection method were used to screen MM cell lines with stable silent SPRY2. (spandidos-publications.com)
  • Multiple myeloma (MM) is a type of malignant plasma cell and has a high incidence in malignant tumors of the blood system, accounting for ~2% of the total mortality of cancer ( 1 ). (spandidos-publications.com)
  • Maplirpacept (TTI-622) is under development for the treatment of relapsed and refractory multiple myeloma, acute myelocytic leukemia, relapsed and refractory lymphoma, indolent non-Hodgkin's lymphoma, classic Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, peripheral T-cell lymphomas (PTCL) and cutaneous T-cell lymphoma, solid tumors and platinum-resistant epithelial ovarian cancer (EOC), fallopian tube carcinoma (FTC) or primary peritoneal carcinomas (PPC). (globaldata.com)
  • After partial resection of the tumor the histology indicated Hodgkin's disease-mixed cellularity. (hindawi.com)
  • He suffered recurrent pulmonary infections and succumbed to severe pneumonia with respiratory failure and pulmonary hypertension five years after the diagnosis of malignant lymphoma without evidence of recurrence of Hodgkin's disease. (hindawi.com)
  • The product is currently undergoing Phase I testing in patients with solid tumors and non-Hodgkin's lymphomas. (pharmatimes.com)
  • Antineoplastons are nontoxic substances that have shown to be a promising therapy for difficult-to-treat brain cancers, low- and intermediate-grade non-Hodgkin's lymphoma, and many common types of solid tumors. (cancure.org)
  • Keytruda, a human PD-1 blocking antibody, is indicated for the treatment of metastatic melanoma, non-small cell lung cancer, recurrent or metastatic head and neck squamous cancer, advanced/metastatic urothelial cancer and classical Hodgkin's lymphoma. (cms.gov)
  • Modeled populations included US adult HSCT recipients (base case), patients with human immunodeficiency virus (HIV), patients with breast cancer, patients with Hodgkin's lymphoma, and renal transplant recipients. (bvsalud.org)
  • Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (medscape.com)
  • Thomas RK, Re D, Wolf J, Diehl V. Part I: Hodgkin's lymphoma--molecular biology of Hodgkin and Reed-Sternberg cells. (medscape.com)
  • Re D, Kuppers R, Diehl V. Molecular pathogenesis of Hodgkin's lymphoma. (medscape.com)
  • Characteristics of Hodgkin's lymphoma after infectious mononucleosis. (medscape.com)
  • Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. (medscape.com)
  • A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). (medscape.com)
  • Overview of Lymphoma Lymphomas are a heterogeneous group of tumors arising in the reticuloendothelial and lymphatic systems. (msdmanuals.com)
  • In addition to getting further information about the proportion of pediatric patients whose tumors have genetic alterations that can be targeted by select drugs, the primary endpoint for each matched drug is the overall response rate, or the proportion of patients whose tumors shrink by a predefined amount over a specific time period. (childrensoncologygroup.org)
  • Non-Hodgkin lymphoma (NHL) accounts for 4% of all cancers 1 and resulted in an estimated 199,700 deaths worldwide in 2012. (haematologica.org)
  • For each cancer discussed in the first part of our overview, as well as in Part II, which will deal with more common cancers, we briefly cover the tumor biology, how targeting was achieved, the introduction of immune modulation or immune-conjugates, and the impact these therapies are having in the disease. (cancernetwork.com)
  • The situation with solid tumors is considerably more complex, and the evolution of targeted therapies for these cancers is still in its infancy. (cancernetwork.com)
  • Seattle Children's offers investigational CAR T-cell clinical trials for more types of childhood cancers including leukemia, lymphoma, brain and spinal cord tumors, and solid tumors than anywhere else. (seattlechildrens.org)
  • [ 1 ] This article focuses on cutaneous paraneoplastic syndromes caused by solid tumors. (medscape.com)
  • There are several variants of cutaneous melanocytic tumors, characterized by differing clinical and pathologic features. (atlasgeneticsoncology.org)
  • Spitz tumors include a group of cutaneous melanocytic tumors that share certain histologic features. (atlasgeneticsoncology.org)
  • Tessa is currently conducting two pivotal studies of autologous cell therapies in nasopharyngeal cancer and classical Hodgkin lymphoma. (biospace.com)
  • The alpha-fetoprotein was significantly increased and the diagnosis of a germ-cell tumor or neuroblastoma was suspected. (hindawi.com)
  • D. C. Strollo, M. L. Rosado-de-Christenson, and J. R. Jett, "Primary mediastinal tumors-part II: tumors of the middle and posterior mediastinum," Chest , vol. 112, no. 5, pp. 1344-1357, 1997. (hindawi.com)
  • In May, 2017, the FDA granted accelerated approval for the use of Keytruda for treatment of patients with unresectable or metastatic solid tumors having either microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) biomarkers. (cms.gov)
  • Fifteen dogs with lymphoma referred to Oncology Unit in the Veterinary Hospital of São Paulo State University (UNESP/Jaboticabal) were included in this study. (vin.com)
  • Guideline] NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma. (medscape.com)
  • This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. (fredhutch.org)
  • Genetic tests look at the unique genetic material (genes) of patients' tumor cells. (fredhutch.org)
  • Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas. (fredhutch.org)
  • This phase II Pediatric MATCH trial studies how well palbociclib works in treating patients with Rb positive solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations (mutations) in cell cycle genes that have spread to other places in the body and have come back or do not respond to treatment. (clinicaltrialsgps.com)
  • complete response + partial response) in pediatric patients treated with palbociclib with advanced solid tumors (including central nervous system [CNS] tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor activating genetic alterations in cell cycle genes. (clinicaltrialsgps.com)
  • I. To estimate the progression free survival in pediatric patients treated with palbociclib with advanced solid tumors (including CNS tumors), non-Hodgkin lymphomas or histiocytic disorders that harbor activating genetic alterations in alterations in cell cycle genes. (clinicaltrialsgps.com)
  • The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. (sutterhealth.org)
  • Three separate cohorts of patients (with diffuse large B-cell lymphoma, mantle cell lymphoma, or follicular lymphoma) received buparlisib 100 mg once daily until progression, intolerance, or withdrawal of consent. (haematologica.org)
  • Overall, 72 patients (26 with diffuse large B-cell lymphoma, 22 with mantle cell lymphoma, and 24 with follicular lymphoma) were treated. (haematologica.org)
  • two patients (one each with diffuse large B-cell lymphoma and mantle cell lymphoma) achieved a complete response. (haematologica.org)
  • This antibody is currently being evaluated in multiple clinical studies in patients with myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin lymphoma, and solid tumors. (pharmiweb.com)
  • Granotax was a prospective, open label, multicentre, national phase IV study that evaluated the incidence and severity of neutropenia in adult patients with solid tumors being treated with a docetaxel-based regimen while receiving the GCSF lenograstim. (hindawi.com)
  • No recurrences were observed among the patients with appendiceal primary tumors treated with appendectomy alone, which supports resection of the appendix without hemicolectomy as the procedure of choice. (oncolink.org)
  • In adults, it has been accepted practice to remove the entire right colon in patients with large neuroendocrine tumors of the appendix (>2 cm in diameter) or with tumors that have spread to the lymph nodes. (oncolink.org)
  • The Italian Tumori Rari in Etá Pediatrica project performed a prospective registry study that evaluated 113 patients with appendiceal neuroendocrine tumors. (oncolink.org)
  • Thirty-five patients had extension of tumor beyond the appendiceal wall. (oncolink.org)
  • The five patients with tumors larger than 2 cm did well. (oncolink.org)
  • Pediatric MATCH is a phase 2 trial that investigates different study drugs, each targeting a defined set of gene mutations, in order to match patients with therapies aimed at the molecular abnormalities in his or her tumor. (childrensoncologygroup.org)
  • Patients must have a tumor that is a candidate for genetic testing and have completed genetic testing which indicates the tumor contains certain genetic changes that are targeted in the study. (childrensoncologygroup.org)
  • Patients with a matched drug will be able to receive experimental treatment for as long as their tumors are stable in size or getting smaller. (childrensoncologygroup.org)
  • NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of LOXO-101 in patients with tumors harboring actionable NTRK fusions. (childrensoncologygroup.org)
  • Although PD-1/PD-L1 inhibitors have transformed the treatment paradigms of several tumor types, the therapies yield deep and durable responses in a minority of patients. (onclive.com)
  • They looked at the rate of malignances overall or secondary malignancies between the 2 arms, and there was a slightly higher rate of secondary malignancies seen with the patients who received ABVD, and for some reason, that was not related to patients getting secondary solid tumors, as the rates of solid tumors were actually the same. (reachmd.com)
  • Currently, there is no possibility to detect early tumor response in lung cancer patients within the first days after chemotherapy (CTx) or tyrosine kinase inhibitor (TKI) therapy induction. (esmo.org)
  • The company also highlighted progress with omidubicel , an advanced cell therapy with positive Phase 3 clinical data, as a potentially life-saving treatment option for patients in need of an allogeneic hematopoietic stem cell (bone marrow) transplant, and GDA-201 , a natural killer (NK) cell immunotherapy in Phase 1/2 development for patients with non-Hodgkin lymphoma (NHL). (biospace.com)
  • Close to 10 percent of our new patients have lymphoma. (valleychildrens.org)
  • Approximately 30 percent of our new patients suffer from solid tumors. (valleychildrens.org)
  • This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors. (ucbraid.org)
  • Most patients with Hodgkin lymphoma present with painless cervical adenopathy. (msdmanuals.com)
  • Les concentrations sériques de sCD40L circulant et d'interleukine 10 circulante ont été analysées à l'aide de la méthode immuno-enzymatique chez 30 patients positifs pour le VHC avec un CHC, chez 30 patients patients positifs pour le VHC avec une cirrhose du foie, et chez 30 volontaires d'âge correspondant en bonne santé avec des anticorps anti-VHC négatifs servant de groupe témoin. (who.int)
  • HUTCHMED plans to develop and seek approval for TAZVERIK ® in various hematological and solid tumors, including ES, FL and diffuse large b-cell lymphoma ("DLBCL") in its Territory. (businesswire.com)
  • ATG-101, given at 3.25 mg/kg or 13 mg/kg, was found to potentially inhibit tumor growth in h4-1BB transgenic mice bearing PD-1/PD-L1 inhibitor resistant B16F10 (melanoma) and EL4 (lymphoma) tumor cells. (onclive.com)
  • Solid organ transplant recipients, who are medically immunosuppressed to prevent graft rejection, have increased melanoma risk, but risk factors and outcomes are incompletely documented. (cdc.gov)
  • TAZVERIK ® 's potential for broad applicability and favorable safety profile may provide further inhibition of tumor growth and metastasis when used in combination therapy. (businesswire.com)
  • 2005). Lymphangiogenesis is also important for tumors expansion, especially the for lymph node metastasis (Kadowaki et al . (vin.com)
  • Tumor cells release enzyme to the circulation, probably in connection with the disruption of dead or dying tumor cells. (wikipedia.org)
  • Activation of the phosphatidylinositol 3-kinase/mechanistic target of rapamycin pathway plays a role in the pathogenesis of non-Hodgkin lymphoma. (haematologica.org)
  • Seattle Children's doctors and researchers are leading efforts to better treat leukemia and lymphoma in children and young adults by using CAR T-cell therapy, an experimental cancer treatment that stimulates the immune system to fight disease. (seattlechildrens.org)
  • This study will evaluate palbociclib in combination with chemotherapy (temozolomide and irinotecan) in children, adolescents and young adults with recurrent or refractory solid tumors. (cincinnatichildrens.org)
  • Doctors and researchers at Seattle Children's are testing CAR T-cell therapy in children and young adults with recurrent or refractory central nervous system (CNS) tumors (tumors of the brain and spine). (seattlechildrens.org)
  • To learn more about available clinical trials related to brain and spinal tumors, contact us at [email protected] or 513-636-2799. (cincinnatichildrens.org)
  • Here, in Part I, we describe areas where major inroads were initially achieved by targeting angiogenesis (central to the biology of renal cell carcinoma and hepatocellular cancer) and by unraveling pathways in the heterogeneous tumors of mesenchymal origin-spurred by the identification of c-Kit-activating mutations in gastrointestinal stromal tumors (GIST) and the regressions that ensued when tumors harboring these mutations were exposed to the tyrosine kinase inhibitor imatinib (Gleevec). (cancernetwork.com)
  • NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice), also known as Pediatric MATCH, is an international pediatric precision medicine cancer treatment trial that explores whether targeted therapies can be effective for children, adolescents and young adults with solid tumors that harbor specific gene mutations. (childrensoncologygroup.org)
  • Unraveling how cancer cells stop the immune system from recognizing tumors as dangerous. (benaroyaresearch.org)
  • cancer in the organs and ducts that make and store bile, the liquid made by the liver), renal cell carcinoma (RCC, a type of cancer that begins in the kidneys), breast cancer, and certain other solid tumors. (medlineplus.gov)
  • Goldberg MS, Al-Homsi N, Goulet L, and Riberdy H. Incidence of cancer among persons living near a municipal solid waste landfill site in Montreal, Quebec. (cdc.gov)
  • Goldberg MS, Seimiatyck J, DeWar R, Desy M, and Riberdy H. Risks of Developing Cancer Relative to Living Near a Municipal Solid Waste Landfill in Montreal, Quebec, Canada. (cdc.gov)
  • Researchers used the Quebec Tumor Registry, a population-based cancer registry, to evaluate whether cancer incidence among persons who lived near the site was higher than the incidence in the reference zones during the period 1981 to 1988. (cdc.gov)
  • An additional source of quantita- erations for compounds that cause of tumour-free animals by 50% (Gold tive data on cancer risks is the group cancer in experimental animals. (who.int)
  • In addition, a deeper understanding of the complex interplay of cells in the tumor microenvironment will lead to therapies directed at the specific mechanism of immune suppression in a specific patient. (genengnews.com)
  • Tessa Therapeutics is a clinical-stage biotechnology company focused on the development of cell therapies for lymphomas and solid tumors. (biospace.com)
  • Some localized melanomas may result from azathioprine, which acts synergistically with ultraviolet radiation, while T-cell depleting induction therapies may promote late stage tumors. (cdc.gov)
  • Drugs used as chemotherapy, such as carboplatin and vincristine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (mayoclinic.org)
  • Giving combination chemotherapy may kill more tumor cells than one type of chemotherapy alone. (ucdavis.edu)
  • Level of evidence C1] Primary re-excision was not recommended for completely excised tumors smaller than 2 cm except for microscopic/macroscopic residual tumor on the margins of the appendix, in which case cecum resection and pericecal node biopsy was recommended. (oncolink.org)
  • Pediatric MATCH is a trial for children, adolescents and young adults ages 1 to 21 who have solid tumors, including non-Hodgkin lymphomas, brain tumors, and histiocytoses, that no longer respond to standard treatment or have recurred after treatment. (childrensoncologygroup.org)
  • We describe areas where major inroads were initially achieved by targeting angiogenesis and by unraveling pathways in the heterogeneous tumors of mesenchymal origin-spurred by the identification of c-Kit-activating mutations in GIST and the regressions that ensued when tumors harboring these mutations were exposed to the tyrosine kinase inhibitor imatinib (Gleevec). (cancernetwork.com)
  • A single-institution retrospective review identified 45 cases of neuroendocrine (carcinoid) tumors in children and adolescents between 2003 and 2016. (oncolink.org)
  • Most neuroendocrine tumors of the appendix are discovered incidentally at the time of appendectomy, and are small, low-grade, localized tumors. (oncolink.org)
  • Study results suggest that appendectomy alone is sufficient treatment for pediatric appendiceal neuroendocrine tumors regardless of size, position, histology, or nodal or mesenteric involvement and that right hemicolectomy is unnecessary in children. (oncolink.org)
  • The study concluded that appendectomy alone should be considered curative for most cases of appendiceal neuroendocrine tumors. (oncolink.org)
  • A French multicenter study of children younger than 18 years with neuroendocrine tumors of the appendix was carried out by surveying pediatric surgeons from 1988 to 2012. (oncolink.org)
  • The investigator's recommendation was that appendectomy alone is sufficient treatment for neuroendocrine tumors of the appendix. (oncolink.org)
  • A systematic review and meta-analysis of 38 studies of appendiceal neuroendocrine tumors identified 958 cases with a mean age at presentation of 11.6 years. (oncolink.org)
  • Safely Skip PET2 After Brentuximab in Hodgkin Lymphoma? (medscape.com)
  • Now that there is an overall survival benefit, I think, really, the field has shifted and I would say most providers are offering brentuximab AVD for any patient with advanced-stage Hodgkin lymphoma, but especially this kind of high-risk patient. (reachmd.com)
  • And so just to summarize, I think in this patient with high-risk advanced-stage Hodgkin lymphoma, I would aim to use brentuximab vedotin [BV] combined with AVD. (reachmd.com)
  • This collaboration will accelerate the exploration of the clinical potential of EZH2 inhibition in multiple tumor types, including both hematological malignancies and solid tumors. (businesswire.com)
  • We also continue to expand our clinical pipeline with plans to submit an IND for our GDA-201 natural killer cell therapy, initiate a multi-center Phase 1/2 clinical study in NHL and continue to advance our R&D activities to pursue the development of genetically modified NAM-enabled NK cells in solid tumors. (biospace.com)
  • This results in killing tumor cells. (mayoclinic.org)
  • As has often been the case, hematologic malignancies have led the way in the introduction of this new generation of therapeutics-perhaps because of easy access to tumor samples for pharmacodynamics, and the narrow spectrum of cells of origin. (cancernetwork.com)
  • Additionally, the findings showed an increase in the infiltration, proliferation, and activation of CD8+ T cells with ATG-101, as well as the infiltration of natural killer T cells and the CD8+/Treg ratio in tumor infiltrating lymphocytes. (onclive.com)
  • The percentage of VEGF-positive tumor cells was scored at 0 to 4 levels (0: less than de 5% of labeled cells to 4: more than 75% of labeled cells). (vin.com)
  • Radiation therapy uses high-energy x-rays to kill tumor cells. (ucbraid.org)
  • Hodgkin lymphoma is a localized or disseminated malignant proliferation of cells of the lymphoreticular system, primarily involving lymph node tissue, spleen, liver, and bone marrow. (msdmanuals.com)
  • Hodgkin lymphoma results from the clonal transformation of cells of B-cell origin, giving rise to pathognomic binucleated Reed-Sternberg cells. (msdmanuals.com)
  • Monitoring treatment response with diffusion-weighted and dynamic contrast perfusion MR imaging has been proposed for some time as a new powerful tool that will allow determining tumor response much earlier than RECIST. (esmo.org)
  • Histological classification showed high-grade lymphomas prevalence (86,7%), corresponding to morphological subtypes: centroblastic (5), immunoblastic (4), lymphoblastic (2) and anaplastic (2). (vin.com)
  • Tessa's Virus-Specific T cell (VST platform) has shown a strong safety profile and early efficacy in the treatment of solid tumors. (biospace.com)
  • At present, and for some years to come, the treatment of most solid tumors will continue to rely on a patchwork of empirically derived and newly introduced molecularly targeted agents. (cancernetwork.com)
  • If there is a genetic abnormality identified in the tumor and a drug in Pediatric MATCH that targets that abnormality, the patient can then enroll in the corresponding treatment arm if he or she meets the eligibility criteria. (childrensoncologygroup.org)
  • So as you described, this patient has stage 4 Hodgkin lymphoma, and this is the kind of patient who, when the ECHELON-1 data first came out, you know, it really seemed, based on subset analyses, that this was the kind of patient who might benefit from the treatment most. (reachmd.com)
  • It also tests whether combination of selinexor and standard radiation therapy works to shrink tumors in this patient population. (ucbraid.org)
  • With this mechanism of action, the therapy is hypothesized to treat tumors without eliciting on-target, off-tumor liver toxicity. (onclive.com)
  • So you have a 27-year-old female patient who has an International Prognostic Score [IPS] of 5 and is diagnosed with stage 4 Hodgkin lymphoma associated with bone and liver involvement. (reachmd.com)
  • Only some of these characteristics are seen in atypical Spitz tumors and spitzoid melanomas. (atlasgeneticsoncology.org)
  • Epithelioid angiosarcoma (EA) is a rare variant of angiosarcoma, which is characterized by a high-grade malignant neoplasm, which consists of an atypical, multilayered, or solid endothelial proliferation and vasoformative architecture, presenting necrosis and an area of hemorrhage 1-5 . (bvsalud.org)
  • 2005). The aim of this study was to investigate the expression of VEGF in dogs with lymphoma by means of immunohistochemistry and its relationship to biological behavior of canine lymphomas. (vin.com)
  • The lymphoma presented as a solid tumor mass in the right upper posterior mediastinum without peripheral lymphadenopathy. (hindawi.com)